Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01124019 · ClinicalTrials.gov registry record
Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 1,600
- Enrollment target
NCT01124019: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT01124019 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 1,600 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01124019 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 1,600 participants
- Enrollment target
Study Summary
The primary objective is to compare the predicted lifetime risk values produced by SNP panel assessment to the risk values produced by the prediction models that are most commonly used. A second objective is to examine whether the incorporation of risk assessment panels (standard or SNP based) can improve the positive value of breast biopsies in women with BIRADS 4 mammograms.
Primary Outcome
The predicted risk category and prevention recommendations which are based upon the category each patient falls into after risk assessment using either a traditional or a SNP-based approach. Change in PPV of mannographic biopsy by stratification into low and high risk groups.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,600 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-10 |
What the finished NCT01124019 record still lists
NCT01124019 is an observational study that tracks outcomes without assigning an intervention. Its 1,600 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01124019 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01124019 about?
NCT01124019 is a clinical study titled "Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography". The primary objective is to compare the predicted lifetime risk values produced by SNP panel assessment to the risk values produced by the prediction models that are most commonly used. A second objective is to examine whether the incorporation of risk assessment panels (standard or SNP based) can i...
What is the current status of trial NCT01124019?
This trial is currently completed. The enrollment target is 1,600 participants. The study started on 2010-02. Estimated completion is 2012-10.
Who is sponsoring clinical trial NCT01124019?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- NCT04314401 · 1,600 participants
National Cancer Institute "Cancer Moonshot Biobank"
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia